Zacks Research Issues Optimistic Forecast for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities research analysts at Zacks Research upped their Q2 2026 earnings per share estimates for Corcept Therapeutics in a report issued on Wednesday, April 2nd. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings of $0.68 per share for the quarter, up from their prior estimate of $0.67. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2026 earnings at $0.83 EPS, Q4 2026 earnings at $0.91 EPS, FY2026 earnings at $2.89 EPS, Q1 2027 earnings at $0.59 EPS and FY2027 earnings at $3.75 EPS.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company had revenue of $181.89 million for the quarter, compared to analyst estimates of $200.12 million.

A number of other analysts have also issued reports on the stock. Piper Sandler increased their price target on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the stock an “overweight” rating in a research report on Thursday. HC Wainwright increased their price objective on Corcept Therapeutics from $115.00 to $150.00 and gave the company a “buy” rating in a report on Monday, March 31st. Canaccord Genuity Group lifted their price objective on Corcept Therapeutics from $130.00 to $142.00 and gave the stock a “buy” rating in a research note on Tuesday. StockNews.com downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. Finally, Truist Financial increased their price objective on Corcept Therapeutics from $76.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, March 31st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $143.25.

Corcept Therapeutics Trading Down 6.2 %

Shares of CORT stock opened at $74.45 on Friday. Corcept Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $117.33. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The stock has a 50-day simple moving average of $64.81 and a 200 day simple moving average of $56.28. The stock has a market capitalization of $7.85 billion, a P/E ratio of 59.09 and a beta of 0.14.

Institutional Trading of Corcept Therapeutics

A number of large investors have recently bought and sold shares of CORT. Kestra Investment Management LLC bought a new position in shares of Corcept Therapeutics in the fourth quarter worth $27,000. Canada Pension Plan Investment Board bought a new stake in Corcept Therapeutics during the fourth quarter worth about $40,000. National Bank of Canada FI bought a new stake in shares of Corcept Therapeutics in the 4th quarter worth approximately $42,000. USA Financial Formulas bought a new position in Corcept Therapeutics during the 4th quarter worth approximately $54,000. Finally, Newbridge Financial Services Group Inc. bought a new position in Corcept Therapeutics in the fourth quarter worth approximately $58,000. 93.61% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Corcept Therapeutics

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $68.08, for a total value of $149,776.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Joseph K. Belanoff sold 35,102 shares of the company’s stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $94.72, for a total value of $3,324,861.44. Following the completion of the transaction, the chief executive officer now directly owns 2,982,335 shares of the company’s stock, valued at approximately $282,486,771.20. This represents a 1.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 163,124 shares of company stock valued at $15,074,318. 20.50% of the stock is owned by corporate insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.